Xin Dong

Xin Dong

Auto-generated profile, based on publicly available information

Xin Dong

Vancouver Prostate Centre, Vancouver, British Columbia, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Differentiation
Verified
Journal Article
Closed access
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
JWJoy X. Wang
Joy X. Wang
HXHui Xue
Hui Xue
DLDong Lin
Dong Lin
XDXin Dong
Xin Dong
JPJun Pang
Jun Pang

4 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
XCXinpei Ci
Xinpei Ci
JHJun Hao
Jun Hao
XDXin Dong
Xin Dong
HXHui Xue
Hui Xue
RWRebecca Wu
Rebecca Wu
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. It develops mainly via NE transdifferentiation of prostate adenocarcinoma in response to androgen receptor (AR)-inhibition therapy. The study of NEPC development has been hampered by a lack of clinically relevant models. We previously established a unique and first-in-field patient-derived xenograft (PDX) model of adenocarcinoma (LTL331)-to-NEPC (LTL331R) transdifferentiation. In this study, we applied conditional reprogramming (CR) culture to establish a LTL331 PDX-derived cancer cell line named LTL331_CR_Cell. These cells retain the same genomic mutations as the LTL331 parental tumor. They can be continuously propagated in vitro and can be genetically manipulated. Androgen deprivation treatment on LTL331_CR_Cells had no effect on cell proliferation. Transcriptomic analyses comparing the LTL331_CR_Cell to its parental tumor revealed a profound downregulation of the androgen response pathway and an upregulation of stem and basal cell marker genes. The transcriptome of LTL331_CR_Cells partially resembles that of post-castrated LTL331 xenografts in mice. Notably, when grafted under the renal capsules of male NOD/SCID mice, LTL331_CR_Cells spontaneously gave rise to NEPC tumors. This is evidenced by the histological expression of the NE marker CD56 and the loss of adenocarcinoma markers such as PSA. Transcriptomic analyses of the newly developed NEPC tumors further demonstrate marked enrichment of NEPC signature genes and loss of AR signaling genes. This study provides a novel research tool derived from a unique PDX model. It allows for the investigation of mechanisms underlying NEPC development by enabling gene manipulations ex vivo and subsequent functional evaluations in vivo.

2 June 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ZDZhi Duan
Zhi Duan
MSMingchen Shi
Mingchen Shi
AKAnbarasu Kumaraswamy
Anbarasu Kumaraswamy
DLDong Lin
Dong Lin
DKDhruv Khokhani
Dhruv Khokhani
JAJoshi J. Alumkal
Joshi J. Alumkal
Lineage plasticity is recognized as a critical determinant of lethality and resistance to AR pathway inhibitors in prostate cancer. Lineage plasticity is a continuum, ranging from AR activity-low tumors, AR-null tumors that do not express a neuroendocrine prostate cancer (NEPC) program (i.e., double-negative prostate cancer [DNPC]), and AR-null NEPC tumors. Factors upregulated early in lineage plasticity are not well-characterized. The clarification of such factors is essential to identify tumors undergoing lineage plasticity or at risk of this occurring. Our integrative analysis of metastatic prostate cancer patient tumors, patient-derived xenografts, and cell models determined that PROX1 is upregulated early in the lineage plasticity continuum and progressively increases as tumors lose AR activity. We determined DNA methylation is a key regulator of PROX1 expression. PROX1 suppression in DNPC and NEPC reduces cell survival and impacts apoptosis and differentiation, demonstrating PROX1’s functional importance. PROX1 is not directly targetable with standard drug development approaches. However, affinity immunopurification demonstrated histone deacetylases (HDACs) are among the top PROX1-interacting proteins; HDAC inhibition depletes PROX1 and recapitulates PROX1 suppression in DNPC and NEPC. Altogether, our results suggest PROX1 promotes the emergence of lineage plasticity, and HDAC inhibition is a promising approach to treat tumors across the lineage plasticity continuum.

5 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
NWNelson Wong
Nelson Wong
XDXin Dong
Xin Dong
YLYen-Yi Lin
Yen-Yi Lin
HXHui Xue
Hui Xue
RWRebecca Wu
Rebecca Wu
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
Androgen deprivation therapy (ADT) is the standard therapy for men with advanced prostate cancer (PCa). PCa often responds to ADT and enters a dormancy period, which can be recognized clinically as a minimal residual disease. However, the majority of these patients will eventually experience a relapse in the form of castration-resistant PCa with poor survival. Therefore, ADT-induced dormancy is a unique time window for treatment that can provide a cure. The study of this well-recognized phase of prostate cancer progression is largely hindered by the scarcity of appropriate clinical tissue and clinically relevant preclinical models. Here, we report the utility of unique and clinically relevant patient-derived xenograft models in the study of the intrinsic immune landscape of dormant PCa. Using data from RNA sequencing, we have reconstructed the immune evasion mechanisms that can be utilized by dormant PCa cells. Since dormant PCa cells need to evade the host immune surveillance for survival, our results provide a framework for further study and for devising immunomodulatory mechanisms that can eliminate dormant PCa cells.

30 June 2017
Verified
Book Chapter
Closed access
PDF file
XDXin Dong
Xin Dong
PGPeter W. Gout
Peter W. Gout
LYLu Yi
Lu Yi
YWYinhuai Wang
Yinhuai Wang
YXYong Xu
Yong Xu
KYKuo Yang
Kuo Yang